In patients with type 2 diabetes (T2D), both young-onset hypertension (onset before the age of 45 years) and late-onset hypertension (onset at the age of 45 years or later) were associated with higher risks for cardiovascular disease (CVD), congestive heart failure, chronic kidney disease, and all-cause mortality, with young-onset hypertension linked to poorer outcomes.

* Idorsia receives approval from Health Canada for JERAYGO (aprocitentan) as the first and only endothelin receptor antagonist (ERA) for the treatment of resistant hypertension.

The Body Scan 2 measures more than 60 biomarkers and notifies users that they're at risk of high blood pressure, rather than issuing a definitive diagnosis.

Enter your email to get Benzinga's ultimate morning update: The PreMarket Activity NewsletterIdorsia receives approval from Health Canada for JERAYGO™ (aprocitentan) as the first and only endothelin receptor antagonist (ERA) for the treatment of resistant hypertension.